Adagio Medical Holdings, Inc. (ADGM)
NASDAQ: ADGM · Real-Time Price · USD
1.400
-0.090 (-6.04%)
At close: Feb 21, 2025, 4:00 PM
1.390
-0.010 (-0.71%)
After-hours: Feb 21, 2025, 6:40 PM EST
Company Description
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias.
It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia.
The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories.
Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
Adagio Medical Holdings, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 85 |
| CEO | Todd Usen |
Contact Details
Address: 26051 Merit Circle, Suite 102 Laguna Hills, California 92653 United States | |
| Phone | 949-348-1188 |
| Website | adagiomedical.com |
Stock Details
| Ticker Symbol | ADGM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002006986 |
| CUSIP Number | 00534B100 |
| ISIN Number | US00534B1008 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Olav B. Bergheim | Chairman and Chief Executive Officer |
| John T. Dahldorf | Chief Financial Officer |
| Hakon Bergheim | Chief Operating Officer |
| Dr. Alex Babkin Ph.D. | Chief Technical Officer |
| Nabil Jubran | Chief Compliance Officer |
| Ilya Grigorov | Vice President of Global Marketing and Product Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 7, 2025 | EFFECT | Notice of Effectiveness |
| Feb 7, 2025 | EFFECT | Notice of Effectiveness |
| Feb 7, 2025 | 424B3 | Prospectus |
| Feb 7, 2025 | 424B3 | Prospectus |
| Feb 5, 2025 | 424B3 | Prospectus |
| Feb 5, 2025 | 424B3 | Prospectus |
| Feb 5, 2025 | 8-K | Current Report |
| Feb 4, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |